Amedisys (Nasdaq: AMED ) reported earnings on Aug. 7. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Amedisys met expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue increased slightly and GAAP earnings per share contracted significantly.
Margins dropped across the board.
Amedisys booked revenue of $378.5 million. The 11 analysts polled by S&P Capital IQ predicted revenue of $375.5 million on the same basis. GAAP reported sales were 1.3% higher than the prior-year quarter's $373.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.27. The 11 earnings estimates compiled by S&P Capital IQ anticipated $0.24 per share. GAAP EPS of $0.26 for Q2 were 65% lower than the prior-year quarter's $0.75 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.9%, 440 basis points worse than the prior-year quarter. Operating margin was 4.1%, 610 basis points worse than the prior-year quarter. Net margin was 2.1%, 370 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $376.0 million. On the bottom line, the average EPS estimate is $0.26.
Next year's average estimate for revenue is $1.50 billion. The average EPS estimate is $0.99.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 834 members out of 927 rating the stock outperform, and 93 members rating it underperform. Among 201 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 168 give Amedisys a green thumbs-up, and 33 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Amedisys is hold, with an average price target of $12.61.